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SUMMARY
There have been considerable advances in the 
management of patients with lymphoma over the past 
three decades. In Hodgkin’s disease, there was a 
major break-through in the late 1960s with the 
development of the MOPP combination regimen.
Using this and other more recent combinations, 
remission rates of up to 80 pc may be achieved overall 
with many patients having durable remissions. In 
non-Hodgkin’s lymphoma there have been few 
advances in therapy of the indolent low-grade 
varieties which remain largely incurbable. In the 
aggressive high-grade lymphomas, some subtypes 
have proved highly responsive to intensive cytotoxic 
programmes, giving remission rates and relapse-free 
survival rates of 70-80 pc. Certain categories, 
however, such as lymphoblastic lymphoma, remain a 
problem . Bone marrow transplantation and 
biological response modifiers have been important 
recent developments. The search for treatment 
strategies that improve survival and have relatively 
low toxicity is a continuing challenge. 
Abbreviations: CT = C hem otherapy, RT = 
Radiotherapy, TBI = Total body irradiation, ABMT= 
Autologous bone marrow transplantation, BMT = 
Bone marrow transplantation, BRM = Biological 
response m odifiers, NHL = Non H odgkin’s 
lymphoma and HD = Hodgkin’s disease.
INTRODUCTION
The field of lymphoma thernny has proved to be one 
of the most rapidly developing areas in medicine. 
During the past two to three decades, greater 
understanding of the histological patterns and disease 
processes has led to important advances in tumour 
definition, staging and therapeutic approaches. 
Scientists have collaborated closely with clinicians in 
defining the mode of action and adverse effects of 
cytotoxic agents, and well-structured clinical trials 
have been performed. The introduction of oncology 
centres which utilise the services of many experts 
from different specialities in a co-ordinated manner 
has also contributed to the improved results seen 
today. Several different treatment modalities are now 
availab le , including surgery, radiotherapy, 
chemotherapy, bone marrow transplantation and 
biological and immunological approaches. The 
progress achieved has led to the despondency of the 
past being replaced by optimism. Advances in 
lymphoma treatment are reviewed in this paper. 
HODGKIN’S DISEASE: Radiotherapy was the 
earliest form of lymphoma treatment.1 Widefield 
techniques with irradiation of multiple node chains 
were introduced and tumoricidal dose levels
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identified. For many years, radiotherapy was the 
only effective treatment modality, Nitrogen mustard, 
the first cytotoxic drug, was used for HD in the 1940s 
with little success. As other drugs became available 
e.g. cyclophosphamide and vincristine, they were 
used as single agents to treat HD, with results little 
better than in untreated patients.4 The design of early 
drug combinations was based on considerations of 
pharmacological action and tumour cell kinetics. The 
major breakthrough came with the development of 
the MOPP regimen (mustine, oncovin, procarbazine 
and prednisolone). This combination led to a 
number of lasting remissions in patients with 
advanced disease. Thus in the 1960s with 
improvements in radiotherapy and the advent of 
MOPP, the possibility of cure for Hodgkin’s disease 
was raised for the first time.
Since then many more reports have confirmed the 
efficacy of MOPP which produces remission rates of 
up to 80 pc in patients with advanced stage disease.4'6 
But although the initial remission rate is high, a 
number of patients relapse. The proportions vary 
from 14-50 pc in different studies. ' In addition, 
with improved survival a number of complications 
became evident, the most important being growth
O
retardation, infertility and second malignancies.
Because of this, many com plem entary or 
alternative chemotherapy approaches have been 
investigated, including extending the duration of 
treatment, the addition or substitution of drugs such 
as chlorambucil, adriamycin and the nitrosources, 
alternating sequences of non-cross-resistant agents or 
supplementing chemotherapy with irradiation. None 
of the MOPP-modified regimens have yielded 
im proved resu lts , but the in troduction  of 
non-cross-resistant programmes such as ABVD 
(adriamycin, bleomycin, vinblastine, dacarbazinc) 
appears to improve survival with fewer side effects.8
For many years, combined modality treatment has 
been used in all stages of HD. The current trend is in 
the direction of employing lower doses of irradiation. 
Encouraging results are reported by some10 but not 
others.11
The standard treatment approach today for Stage I 
and II disease is radiation therapy alone, i.e. ‘mantle’ 
or ‘inverted Y’ fie lds.12 Good resu lts  with 
relapse-free survival rates of 75-90 pc have been
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11obtained, but there is a high incidence of 
recurrence. For this reason, some oncologists are now 
advocating the use of cytotoxics for all stages,14 an 
approach first used in Uganda.15
The optimal management of State IIIA is still 
debated. Relapse-free survival with radiotherapy 
alone is lower than with Stage I and II disease,13,16 
For Stage IIIB and IV disease, chemotherapy is the 
treatment of choice. The largest experience has been 
with MOPP but alternating non-cross-resistant 
programmes provide a rational alternative and may 
prove superior.
Over the years, the concept of dose intensity (total 
equivalent dose) when devising new cytotoxic 
regimens has received much attention. The 
combination of active drugs with non-overlapping 
toxicity is sound strategy, as drug doses can often be 
increased sufficiently to overcome drug resistance of 
the tumour without significant adverse effects. This 
concept has made possible many of the successes of 
combination CT both in HD and NFIL. Methods of 
identifying the optimum combination of active drugs 
have been devised, reducing the number of clinical 
trials that would otherwise be needed.17
In spite o f th is, tox ic ity , particu larly  
myclosupprcssion, is often a limiting factor. Because 
of this the role of bone marrow transplantation has 
become important in recent years, as it allows the 
administration of cytoreductive therapy with curative 
intent without regard to lethal marrow effects. 
Results from the largest published series of ABMT in 
patients with HD show that about half (43-48 pc) of 
patients not responding to primary induction therapy 
obtained complete remission, and in 24-34 pc these 
remissions were m aintained.18 Toxicity  and 
morbidity are, however, high (death rate 10 pc).
It is not clear which patients would benefit most 
from this procedure, as the patients studied to date arc 
mainly those who do not obtain a remission with CT, 
or who relapse early or repeatedly. Earlier transplants 
in high risk patients may improve survival. 
Suggestions of means of identifying such patients 
include elevated ESR or scrum alkaline phosphatase, 
anaemia or unfavourable histology.
Questions still remain about the most effective 
conditioning programme (CBV-cyclophosphamidc, 
BCNU and etoposide is currendy the most popular) 
and whether dose escalations or addition of 
radiotherapy would improve results or just increase 
toxicity. Most work has been done on autologous
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BMT which carries no risk of graft-versus-host 
disease. Allogenic marrow, however, has the possible 
advantage of a grant-versus-Hodgkin’s disease effect 
and no risk of reinfusing tumour cells. Most workers 
favour autologous BMT but the issue of ‘purging’ the 
marrow of tumour cells using immunological or 
pharmacological methods is another controversial 
area.
A new and totally different approach is that of 
biological response mediators. This is discussed later.
In the past 25 years, disease-free survival for 
advanced Hodgkin’s disease has risen from zero to 
over 60 pc.19 The question is no longer whether cure 
is possible but how it may best be achieved. 
NON -HODGKIN’S LYMPHOMA: The first 
e ffec tiv e  form of therapy  iden tified  for 
non-Hodgkin’s lymphoma was irradiation, but less 
than 10 pc of all patients were rendered permanently 
free of disease."0 Although progress has parallelled 
the advances in Hodgkin’s disease, the evolution in 
treatment strategy is more difficult to document 
because of the differing clinical features and natural 
history of the various subtypes.
High and intermediate grade non-Hodgkin’s 
lymphoma: Follow ing the success in HD, 
combination therapy was applied to NHL but with 
less satisfactory results. In 1975, Dc Vita and 
co-workcrs published the first report of disease-free 
survival in a fraction of patients with advanced 
diffuse high grade lymphoma using combination CT 
(MOPP or MOPP plus cyclophosphamide).21 These 
and various similar combinations gave complete 
remission rates of 20-60 pc,22 but results were 
inferior in clinically aggressive sub-groups with 
diffuse histology.
During the 1970s, the activity of adriamycin was 
established and this is the most effective agent to date 
for high grades of NHL. Various combinations 
in co rp o ra tin g  th is drug such as CHOP 
(cyclophosphamide, adriamycin, oncovin and 
prednisolone) and BACOP or CHOP-BIco (CHOP + 
bleomycin) have led to complete remission rates of 
40-70 pc in patients with extensive disease, with 
approximately half of the responders remaining 
disease-free for several years.22, 3
More intensive regimens were then developed, 
such as M-BACOD (methotraxatc, bleomycin, 
doxorubicin, cyclophospham ide, vincristine, 
dexam ethazone), A-COM LA (adriam ycin ,
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cyclophosphamide, vincristine, methotrexate, 
leucovorin and cytarabine) and many other complex 
combinations. These have produced complete 
remission rates 55-84 pc and greater than 75 pc 
relapse-free survivals.24 These in tensive 
programmes exhibit considerable toxicity and it has 
not been clearly documented that CHOP, delivered in 
full dosage, is inferior. Several newer chemotherapy 
agents are currently being evaluated, including 
etoposide, cis-platinum, pyrazofurin, vindesine, 
M-AMSA and clorozotocin.25,26 The evolution of 
new chemotherapy concepts has results in new 
chemotherapeutic approaches, which still require 
clinical confirmation.
Certain subsets of aggressive NHL, such as 
lymphoblastic and Burkitt’s, have a poor prognosis if 
treated with conventional programmes, the reasons 
being are that they exhibit a high nervous system 
recurrence rate and also rapidly become refractory to 
chemotherapy. Thus central nervous system 
prophylaxis is important, plus use of multiple agents 
to prevent emergence of a resistant clone of cells. 
Many workers feel that lymphoblastic lymphoma is 
best treated as ALL. In Burkitt’s lymphoma, 
combinations of cyclophosphamide, vincristine, 
cytosine arabinoside and methotrexate27,28 have 
produced longer remissions than cyclophosphamide 
alone. The use of adriamycin may improve results.
The role of radiotherapy in the treatment of high 
and intermediate non-Hodgkin’s lymphoma is less 
well-defined than in Hodgkin’s disease, but the 
results are considerably poorer in Stage II than Stage 
I.22 True Stage I disease is rare. In addition, relapse 
occurs commonly. With more extensive disease, 
radiotherapy is seldom adequate to eradicate disease.
The value of combined modality treatment is not
clear. Radiotherapy in various forms has been
combined with cytotoxic combinations with
23promising results in early stage disease. A report in 
which patients with advanced stage NHL were 
treated with CHOP and total body irradiation 
suggests a possible advantage for combined modality 
therapy.30
Current recommendations therefore are that RT 
may be successful in patients with localised areas of 
involvement, but for all stages beyond this cytotoxics 
are required. The recognition that CT can produce 
long term relapse-free survival in patients with 
advanced disease has prompted its use in all stages.
The natural history of these aggressive lymphomas is 
so poor whatever the chosen therapy, it is important 
to treat early and maximally. The goal is complete 
remission, as only these patients demonstrate 
prolonged survival and potential for cure.
Despite the uncertainty about the best regimen, 
certain principles in the treatment of high grade NHL 
have been established. For a regimen to be curative 
in a substantial number of patients, it must achieve a 
high rate of complete remission with frontline 
therapy, and drugs should be delivered at maximum 
dose intensity . Prolonged treatm ent is not 
necessary.25 Although there is a high rate of early 
relapse, there are few relapses beyond two years. The 
dose intensity can now be augmented by using 
recombinant growth factors, which reduce the 
severity  and duration of treatm ent-induced 
leucopenia.26
Thus over the past two decades, improved 
aggressive combination chemotherapy regimens for 
advanced intermediate and high grade NHL have 
resulted in greatly improved complete remission and 
cure rates. In a significant number of patients, 
however, the disease is refractory to initial therapy or 
relapse occurs. Such patients have a particularly poor 
prognosis. Recent studies suggest that high dose CT 
and/or RT plus BMT arc effective.31 As with HD, the 
dose limiting toxicity with CT’s myclosupprcssion, 
thus BMT has come to play an important role as 
salvage therapy. Long term disease-free survival after 
BMT ranges from 20-50 pc in different studies. "
The status of the tum our at the tim e of 
transplantation is important. Patients transplanted 
early in the course of disease do much better than 
those having drug-resistant relapses (three years 
disease-free survival < 10 pc),3" or who have been 
heavily pretreated. Several groups have evaluated 
the role of high dose CT plus ABMT given during 
first remission as consolidation or intensification in 
patients believed to be at high risk for relapse. 
Although patient numbers are small and several 
histological types are included, the overall complete 
remission rate is approximately 66-70 pc and several 
patients have survived more than two years and are 
still disease-free.31,33
Because of the excellent early results, bone 
marrow transplantation should no longer be used as 
salvage therapy only in NHL but should be 
considered at an early stage (ic first remission) in
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patients with poor prognostic features (e.g. adverse 
h isto logy , high bulk d isease , high lactic
dehydrogenase, anaemia).
LOW  G RA D E N O N -H O D G K IN ’S LYM ­
PH OMA: The low grade lymphomas are usually 
indolent clinically and of advanced stage at 
diagnosis. They are highly responsive to a variety of 
ueatments.
l or Stage I and II disease regional field and total 
lymphoid irradiation, combined RT and CT, and CT 
alone have been used.34 Studies are limited because 
of the rarity of this presentation, but long term 
disease-free survival may be achieved particularly in 
patients below 40 years of age.33
In most patients, involvement is widespread at 
presentation. The management of Stage III and IV 
disease is controversial because standard approaches 
have not proved curative despite high remission rates. 
Significant advantages of various regimens have 
been difficult to prove because of the lengthy 
observation needed, small patient numbers and 
toxicity of intensive therapy in older patients.
Some trials of single alkylating agent (usually 
chlorambucil), combined CT, TBI or both CT and RT 
have shown no significant difference in complete 
remission rates (65-83 pc), relapse-free survival (50 
m onths m edian) or overall surv ival (60+ 
months).34'35,36 Other studies, however, have shown 
better relapse-free survival with combination CT 
though remission rates and median survival are 
similar.37 There appears to be little correlation 
between dose intensity and remission though 
relapse-free survival improves as dose intensity 
increases. Fludarabine is a promising new drug 
currcnUy under evaluation.
In 1979, Portlock and Rosenberg suggested no 
specific therapy for indolent low grade lymphoma 
until dictated by symptoms.38 They found that 
ultimate survival was not significantly different from 
that of comparable patients treated more intensively. 
Later studies, however, tend to support prompt 
treatment at diagnosis. Whatever treatment is used, 
the disease-free survival curves demonstrate a 
constant risk of relapse at a rate of 10-15 pc per 
year.36 Adverse prognostic features include degree of 
nodularity, presence of B symptoms, bulk disease, 
elevated serum lactic dehydrogenase and anaemia.
As more sensitive molecular methods have been 
developed, it has been shown that most patients in
complete remission have circulating monoclonal B 
lymphocytes present. These cells may explain the 
continuous late relapses seen in advanced low grade 
NHL, and may prove useful as a prognostic 
indicator.36
An important biological feature of low grade 
lymphomas is the emergence of an aggressive 
histological subtype with a short survival time. 
ABMT has been studied in these patients but the 
prognosis is still poor.
There is little data available regarding ABMT in 
low grade histologies.
New approaches and future trends: Over the past 
two to three decades, great therapeutic advances have 
been made using combined CT, RT and BMT. Some 
results are excellent but there are still patients treated 
who can neither be cured nor benefit from prolonged 
survival times. In addition, patients have an increased 
risk of developing second m alignancies or 
myelodysplastic syndromes. There was thus a need 
to develop new therapeutic concepts and much 
attention recently has been directed towards the fields 
of immunology and biological response modifiers.
The work began with primitive immunostimulants 
but now encompasses a spectrum of agents including 
interferons, interleukin 2, tumour necrosis factor, 
lymphokine activated killer cells, hacmotopoictic 
growth factors and monoclonal antibodies.
Most cytokines act principally through their 
effects on the immune system, enabling some 
patients to mount an effective anti-tumour response. 
Some have a synergistic effect when used with 
cytotoxic agents, some have anti-tumour activity,and 
the growth factors lead to accelerated recovery from 
myelosuppression.
Of the cytokines, the interferons have been most 
fully studied, and in the lymphomas some interesting 
results have been obtained. Objective response rates 
to alpha-in terferon  of 4 0 -50  pc have been 
documented in low grade NHL. Responses are partial 
with median duration of 6-12 months, and are not 
significantly influenced by histology, stage, or prior 
treatment. The lower response rate of 10-15 pc for 
agg ressive  NHL and HD has been 
discouraging. ' ’ ’ Combinations of interferons 
and cytotoxics appear more promising, but toxicity is 
a problem.
Interleukin-2 has been used only minimally in the 
treatment of NHL to date, but early results are 
encouraging.
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Studies have been performed with monoclonal 
antibodies, but their use has been limited by technical 
difficulties and the results are variable.44 In general, 
responses have been partial and transient but 
dramatic improvement has been recorded in 
occasional cases. In all fields of biotherapy better 
results are obtained when the tumour load is low and 
the immune system not compromised.
Immunisation with tumour antigen to prevent 
relapses and/or prolong survival is another interesting 
concept which may be developed further.44
While these complex biological approaches are 
still experimental and have as yet led to cure in only 
small numbers of patients, it appears they may have 
a role to play in the future.
CONCLUSIONS
With these developments in treatment, many patients 
with HD are now curable. In NHL a paradox has 
become evident. The 'favourable’ prognostic groups 
(low-grade NHL) — so-called because of indolent 
natural history and slow progression — are with few 
exceptions in cu rab le  by cu rren t m ethods. 
Conversely, with ‘unfavourable’ or high-grade 
histology, a considerable proportion of complete 
responders remain free of disease. With this latter 
group, initial selection of an appropriate treatment is 
essential as the possibility of achieving cure is 
notable inferior in previously treated patients. Bone 
marrow transplantation has been an exciting 
development and has a definite role to play in 
carefully selected patients.
These advances mean that many patients with 
lymphomas that were previously universally fatal can 
either be cured or have substantial palliation. In some 
groups, however, the survival results are still 
unsatisfactory and several controversial issues 
remain. The optimal therapeutic strategy for many 
patients is uncertain.
The value of other technique in treatment such as 
b iological response m odifiers, m onoclonal 
antibodies and other forms of immunotherapy will, 
hopefully, soon become clearer. The definition and 
value of prognostic determinants is becoming 
increasingly important and may greatly influence 
selection and outcome.
As superior treatment programmes improve 
survival rates in all the lymphomas, further vital
issues arise, such as the long-term cumulative drug 
effects on tissues and the sequelae from mutagenic 
and carcinogenic agents. The development of 
programmes that improve both survival and safety is 
an on-going challenge.
REFERENCES
1. Craft, C B: Results with roentgen ray therapy 
in Hodgkin’s disease. Bull Staff Meet, Univ 
Minn Hosp 1940; 11: 391-409.
2. K aplan, H S, R osenberg , S A: The 
management of Hodgkin’s disease. Cancer 
1975; 36: 796-803.
3. Gellhom, A, Collins, V P: A quantitative 
evaluation of the contribution of nitrogen 
mustard to the therapeutic management of 
Hodgkin’s disease. Ann Intern Med 1951; 35: 
1250-59.
1. Hugely, C M, Durant, J R, Moores, R R et a t 
A comparison of the effectiveness in advanced 
Hodgkin’s disease of a combination of drugs 
and a single agent both given intravenously 
over a six-month period. Cancer 1975; 36: 
1227-40.
5. De Vita, V T, Serpick, A: Combination 
chemotherapy in the treatment of advanced 
Hodgkin’s disease. ProcAmer Ass Cancer Res 
1967; 8: 13.
6. McVic, J G, Somers, R: Chemotherapy of 
Hodgkin’s disease comes of age. Br Med J 
1985; 290: 950-51.
7. De Vita, V T, Simon, R N, Hubbard, S m ei a t 
Curability of advanced Hodgkin’s disease: 
Long-term follow-up of M OPP-treated 
patients at the National Cancer Institute. Ann 
Intern Med 1980; 92: 587-595.
8. Bonadonna, G: Chemotherapy strategies to 
improve the control of Hodgkin’s disease: the 
Richard and Hilda Rosenthal Foundation 
Award Lecture. Cancer Res 1982; 42: 
4309-20.
9. Cunningham, J, Mauch, P, Rosenthal, D S, 
Cancllos, G P: Long-term complications of 
MOPP chem otherapy in patients with 
Hodgkin’s disease. Cancer Treat Rep 1982; 
66(4): 1015-22.
10. Straus, DJ, Myers, J, Lee, B J et a t  Treatment 
of advanced H odgkin’s d isease with
121
chemotherapy and irradiation. Am J  Med 24. 
1984; 76: 270-80.
11. Rosenberg, S A, Kaplan, H S, Glatstein, E J, 
Portlock, C S: Combined modality therapy of 
H odgkin’s disease. Cancer 1978; 42: 
991-1000.
12. M cE lw ain , T J: H odgkin’s and 
Non-Hodgkin’s lymphomas. Br J Ilosp Med 
1984; 31: 10-19.
13. Portlock, C S: Hodgkin’s disease. Med Clin 
North Am 1984; 68: 729-40.
14. Jacobs, P, King, H S, Karabus, C el al: 
Hodgkin’s disease in children: a ten-year 
experience in South Africa. Cancer 1984; 53: 
210-213.
15. Olweny, C L M, Ziegler, J L, Berard, C W, 
Templeton, A C: Adult Hodgkin’s disease in 
Uganda. Cancer 1971; 27: 1295-1301.
16. Lister, T A, Dorreen, M S, Faux, M et al: The 
treatment of stage IIIA Hodgkin’s disease, J 
Clin Oncol 1983; 1: 745-49.
17. Simon, R, Korn, E L: Selecting drug 
combinations based on total equivalent dose 
(dose intensity) J Natl Cancer Inst 1990; 18: 
1469-1476.
18. Armitage, J O, Barrett, M J, Carclla , A M et 
al: Bone marrow transplantation in the 
treatment of Hodgkin’s lymphoma: Problems, 
remaining challenges and future prospects.
Rec Res Ca Research 1989; 117: 246-253.
19. W illiams, C K O :  Recent advances in 
chemotherapy of the lymphomas: A review. 
AfrJM edSci 1986; 15: 163-169.
20. Schein,PS, Chabner, B A, Canellos,G Pei al: 
Potential for prolonged disease-free survival 
following combination chemotherapy of 
non-Hodgkin’s lymphoma. Blood 1974; 43: 
181-189.
21. De Vita, V T, Canellos, G, Chabner, B et al: 
Advanced diffuse histiocytic lymphoma, a 
potentially curable disease. Lancet 1975; 1: 
248-50.
22. Horwich, A, Peckham M: “ Bad risk ’’ 
non-Hodgkin’s lymphomas. Semin Hematol 
1983; 20: 35-56.
23. C row ther, A: New approaches to the 
management of patients with non-Hodgkin’s 
lymphoma of high grade pathology. Cancer 
1981;43:417-34.
CENTRAL AFRICAN
JOURNAL OF MEDICINE
Shipp, M A, Harrington, D P, Klatt, MM etal: 
Identification of major prognostic subgroups 
of patients with large cell lymphoma treated 
with m-BACOD or M-BACOD. Ann Intern 
Med 1986; 104: 757-765.
25. Armitage, J O and Cheson, B D: Interpretation 
o f clin ical trials in diffuse large cell 
lymphoma. J  Clin One 1988; 6 (8): 
1335-1347.
26. Yi, P I, C olem an, M, Salt/., L et al: 
Chemotherapy for Large Cell Lymphoma: A 
status update. Semin Oncol 1990; 17 (1): 
60-73.
27. Olweny, C L M, Katongolc-Mbidde, E, 
Kaddu-Mukasa, A et al: Treatm ent of 
Burkitt’s Lymphoma: randomised clinical 
trial of single agent versus combination 
chemotherapy. IntJCancer 1976; 17:436-40.
28. Nkrumah, F K, Perkins, N, Biggar, R J: 
Combination chemotherapy in abdominal 
Burkitt’s lymphoma. Cancer 1977; 40: 
1410-1416.
29. Magrath, I T, Spiegel, R J, Edwards, B K, 
Janus, C: Improved results of chemotherapy 
in young patients with Burkitt’s lymphoma, 
u n d iffe ren tia ted  and lym phoblastic  
lymphoma. Proc Am Ass Cancer Res Am Soc 
Clin Oncol 1981; 22: 520-526.
30. Sullivan, K M, Neiman, PE, Kadin, M E et al: 
Combined modality therapy of advanced 
non-Hodgkin’s lymphoma: an analysis of 
remission duration and survival in 95 patients. 
Blood 1983; 62: 51-61.
31. Williams, S F: The role of bone marrow 
transplantation in the N on-H odgkin’s 
lymphomas. Semin Oncol 1990; 17 (1): 
88-95.
32. Santos, G W: Bone marrow transplantation in 
hematologic malignancies. Cancer 1990; 65: 
786-791.
33. Portlock, C E: Non-Hodgkin’s lymphomas. 
A dvances in d iag n o sis , s tag ing  and 
management. Cancer 1990; 65: 718-722.
34. Haller, D G: Non-Hodgkin’s lymphomas. 
Med Clin North Am 1984; 68: 741-56.
35. Portlock, C S: “Good risk” non-Hodgkin’s 
lymphomas: approaches to management. 
Semin Hematol 1983; 20: 25-34.
Vol. 38, No. 3. March, 1992
122
36. Portlock, C S: Management of low-grade 
Non-Hodgkin’s lymphomas. Semin Oncol 
1990; 17; 51-59.
37. Ezdinli. E Z, Anderson, J R, Melvin, F et al: 
Moderate vs aggressive chemotherapy of 
nodular lymphocytic poorly differentiated 
lymphoma. J Clin Oncol 1985; 3: 769-775.
38. Portlock, C S, Rosenberg, S A: No initial 
therapy for stage III and IV non-Hodgkin’s 
lymphomas of favourable histologic types. 
Ann Intern Med 1979; 90: 10-13.
39. Young, R C, Longo. D L, Glatstein, E et al: 
The treatment of indolent lymphomas: 
Watchful waiting vs aggressive combined 
modality treatment. Semin Hematol 1988; 25: 
11-16.
40. Chabner, B A: In troduction  — New 
Directions in Combination Biotherapy. Semin 
Oncol 1990; 17(l)Suppl 1: 1-2.
41. Applelbaun, F R: The clinical use of 
haem atopoietic growth factors. Semin 
Hematol 1989; 26 (3) Suppl 3: 7-14.
42. Olsen, E A, Rosen, 8 T, Vollmer R T et al: 
Interferon alpha-2a in the treatment of 
cutaneous T-cell lymphoma. J Am Acad 
Dermatol 1989; 20: 395—407.
43. Clark, R H, Dimitrov, N V, Axelson, J A, 
Charmclla, L J, Stott, P: A phase II trial of 
intermittent leukocyte interferon and high 
dose chlorambucil in the treatment of 
non-Hodgkin’s lymphoma resistant to 
conventional therapy. Am J Clin Oncol 1989; 
12: 75-77.
44. Janson, C H, Tehrani, M, W igzell H, 
Mellstedt, H: Rational use of biological 
response m odifiers in hem atological 
malignancies. Leukaemia Res 1989; 13: 
1039-1046.
45. Gilewski, T A, Richards, J M: Biologic 
response m odifiers in N on-H odgkin’s 
lymphoma. Semin Oncol 1990; 17: 74-87.
CENTRAL AFRICAN
JOURNAL OF MEDICINE
123
This work is licensed under a 
Creative Commons
Attribution -  Noncommercial - NoDerivs 3.0 License.
To view a copy of the license please see: 
http://creativecommons.org/licenses/by-nc-nd/3.0/
This is a download from the BLDS Digital Library on OpenDocs
http://opendocs.ids.ac.uk/opendocs/
Institute of 
Development Studies
